Linezolid for treatment of vancomycin-resistant enterococcal peritonitis
- 1 October 2001
- journal article
- case report
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 38 (4), e20.1-e20.3
- https://doi.org/10.1053/ajkd.2001.27729
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Vancomycin-Intermediate and -Resistant Staphylococcus aureus: What the Infectious Disease Specialist Needs to KnowClinical Infectious Diseases, 2001
- Indications for Vancomycin in Dialysis PatientsSeminars in Dialysis, 2000
- Analysis of microbiological trends in peritoneal dialysis–related peritonitis from 1991 to 1998American Journal of Kidney Diseases, 2000
- Risk factors for acquisition of vancomycin-resistant enterococci among patients on a renal ward during a community hospital outbreakAmerican Journal of Infection Control, 2000
- In Vitro Activities of Daptomycin, Vancomycin, Linezolid, and Quinupristin-Dalfopristin against Staphylococci and Enterococci, Including Vancomycin- Intermediate and -Resistant StrainsAntimicrobial Agents and Chemotherapy, 2000
- In Vitro Activities of Linezolid against Important Gram-Positive Bacterial Pathogens Including Vancomycin-Resistant EnterococciAntimicrobial Agents and Chemotherapy, 1999
- Emergence of Vancomycin Resistance inStaphylococcus aureusNew England Journal of Medicine, 1999
- Nine episodes of CPD-associated peritonitis with vancomycin resistant enterococciKidney International, 1996